Table 2 Risk factor analysis for epilepsy.

From: Antiepileptic drugs failed to prevent initial seizures or improve survival outcomes in patients with primary CNS lymphoma

Risk factors

Seizures

(n/all, %)

No seizures

(n/all, %)

OR

OR 95%CI

χ2

P Value

Male

26/36

72.2

102/178

57.3

0.516

0.235–1.135

2.709

0.100

Age ≥ 60

13/36

36.1

109/178

61.2

0.358

0.170–0.753

7.332

0.007

EEG abnormal

21/25

84.0

46/67

68.7

2.397

0.731–7.857

2.082

0.149

Edema zone(≥ 1 cm)

25/33

75.6

88/172

51.2

2.983

1.274–2.982

6.344

0.012

Location of lesion

 Cortical involvement

26/34

76.5

39/169

23.1

10.833

4.541–25.846

28.847

0.000

 Bilateral frontal lobes involvement

7/33

21.2

10/141

7.1

3.527

1.230–10.115

5.498

0.019

 Brainstem involvement

8/33

24.2

16/141

11.3

2.500

0.966–6.427

3.565

0.059

PIM1 mutation

1/10

10.0

14/23

60.87

0.071

0.008–0.664

5.384

0.020

AEDs

9/16

56.2

102/178

57.3

0.980

0.349–2.749

0.007

0.970

Response to MTX (CR/PR)

6/15

40.0

95/170

55.9

0.526

0.179–1.544

1.366

0.243

  1. OR: odds ratio; EEG: electroencephalogram; MTX: methotrexate; AEDs: antiepileptic drugs; CR: complete response; PR: partial response.